Bicalutamide Bluefish 150 mg 노르웨이 - 노르웨이어 - Statens legemiddelverk

bicalutamide bluefish 150 mg

bluefish pharmaceuticals ab - bikalutamid - tablett, filmdrasjert - 150 mg

Levact 2.5 mg/ ml 노르웨이 - 노르웨이어 - Statens legemiddelverk

levact 2.5 mg/ ml

astellas pharma gmbh (1) - bendamustinhydroklorid - pulver til konsentrat til infusjonsvæske, oppløsning - 2.5 mg/ ml

Entocort 3 mg 노르웨이 - 노르웨이어 - Statens legemiddelverk

entocort 3 mg

tillotts pharma gmbh - budesonid - depotkapsel, hard - 3 mg

Multibic 2 mmol/l Kalium 노르웨이 - 노르웨이어 - Statens legemiddelverk

multibic 2 mmol/l kalium

fresenius - natriumklorid / kaliumklorid / natriumhydrogenkarbonat / kalsiumklorid / magnesiumkloridheksahydrat / glukosemonohydrat - hemodialyse-/hemofiltreringsvæske

Multibic 4 mmol/l Kalium 노르웨이 - 노르웨이어 - Statens legemiddelverk

multibic 4 mmol/l kalium

fresenius - natriumklorid / kaliumklorid / natriumhydrogenkarbonat / kalsiumklorid / magnesiumkloridheksahydrat / glukosemonohydrat - hemodialyse-/hemofiltreringsvæske

Ursofalk 250 mg 노르웨이 - 노르웨이어 - Statens legemiddelverk

ursofalk 250 mg

dr. falk pharma gmbh - ursodeoksykolsyre - kapsel, hard - 250 mg

Anagrelide AOP 0.5 mg 노르웨이 - 노르웨이어 - Statens legemiddelverk

anagrelide aop 0.5 mg

aop orphan pharmaceuticals gmbh - anagrelidhydroklorid monohydrat - kapsel, hard - 0.5 mg

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) 유럽 연합 - 노르웨이어 - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Levetiracetam Aristo 100 mg/ ml 노르웨이 - 노르웨이어 - Statens legemiddelverk

levetiracetam aristo 100 mg/ ml

aristo pharma gmbh - levetiracetam - mikstur, oppløsning med druesmak - 100 mg/ ml

Trica 20 mg/ ml 노르웨이 - 노르웨이어 - Statens legemiddelverk

trica 20 mg/ ml

esteve pharmaceuticals gmbh - triamcinolonheksacetonid - injeksjonsvæske, suspensjon - 20 mg/ ml